This study, called the Pancreatic Cancer Early Detection (PRECEDE) Consortium, is looking into ways to find pancreatic cancer (PDAC) early and prevent it. Researchers are studying people who have a higher risk of pancreatic cancer, such as those with a family history of the disease or those with specific genetic changes (like in the ATM, BRCA1, BRCA2, CDKN2A, PALB2, or STK11 genes). The study aims to understand how these factors relate to developing pancreatic cancer over an average of six years. There are no specific interventions or drugs being tested; instead, researchers are collecting information and samples from participants to learn more about the disease. The study plans to include 20,000 participants between 18 and 90 years old.

Study design

This is an observational study, meaning researchers will collect information and samples without providing any specific treatments. It plans to include 20,000 participants.

What's involved

You would provide biosamples (like blood) every 6-12 months. Clinical data and outcomes will also be collected from your medical records.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through study completion, which is an average of 6 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.